^
Association details:
| Biomarker: | HER-2 A775_G776insYVMA |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Exkivity (mobocertinib) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MA11.02 Targeting HER2 Exon 20–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib
Published date:
08/18/2021
Excerpt:
Genetically engineered mouse models (GEMMs) harboring YVMA and G776>VC insertions, allograft (Ba/F3-YVMA insertion) and PDX (NSCLC YVMA insertion) were utilized for the drug testing in vivo....mobocertinib showed strong inhibitory activity in HER2 exon 20YVMA allograft and PDX models....mobocertinib showed a robust inhibitory activity against HER2 exon 20 insertion mutations both in vitro and in vivo.
